Inhibition of autoimmune disease by the immunomodulator linomide correlates with the ability to activate macrophages

Autoimmunity

Volumn 32, Issue 3, 2000, Pages 199-211

  Dahlen, E ^a   Andersson, M ^a   Dawe, K ^a   Tellander, A C ^a   Brunmark, C ^a   Bjork, A ^a   Hedlund, G ^a  

^a Active Biotech Research AB   (Sweden)

Author keywords

B cells; Experimental autoimmune encephalomyelitis; Macrophages; Phenotype

Indexed keywords

ANTIGEN; BIOLOGICAL MARKER; CD11 ANTIGEN; DRUG ANALOG; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ROQUINIMEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGENIC MODULATION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL SURFACE; CONTROLLED STUDY; CORRELATION FUNCTION; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; ENCEPHALOMYELITIS; FEMALE; IN VIVO STUDY; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; RECEPTOR UPREGULATION; STRUCTURE ANALYSIS; TREATMENT OUTCOME;

EID: 0033693276     PISSN: 08916934     EISSN: None     Source Type: Journal    
DOI: 10.3109/08916930008994093     Document Type: Article

References (48)

1. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide
2. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide)
3. Linomide suppresses chronic-relapsing experimental autoimmune encephalomyelitis in DA rats
4. Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines
5. Prevention of diabetes mellitus in non-obese diabetic mice by Linomide, a novel immunomodulating drug
6. Immunomodulation of experimental autoimmune myasthenia gravis with linomide
7. Inhibition of experimental autoimmune neuritis by the immunomodulator linomide
8. Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions
9. Paradoxical effects of LS-2616 (Linomide) treatment in the type II collagen arthritis model in mice
10. Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator
11. Effects of LS-2616 administration upon the autoimmune disease of (NZB x NZW) F1 hybrid mice
12. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis
13. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: A double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation
14. Low dose linomide in Type I juvenile diabetes of recent onset: A randomised placebo-controlled double blind trial
15. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers
16. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers
17. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers
18. Linomide, a novel immunomodulator that prevents death in four models of septic shock
19. Linomide inhibits programmed cell death of peripheral T cells in vivo
20. Linomide enhances apoptosis in CD4+CD8+ thymocytes
21. Mechanism of action of the new immunomodulator LS2616 on T cell responses
22. Immunomodulation of autoimmunity by linomide: Inhibition of antigen presentation through down regulation of macrophage activity in the model of experimental autoimmune encephalomyelitis
23. Linomide, an immunomodulator that inhibits Th1 cytokine gene expression
24. Autoimmune diabetes results from genetic defects manifest by antigen presenting cells
25. Distinction between immunogenicity and tolerogenicity among HBcAg T cell determinants. Influence of peptide-MHC interaction
26. Activation-driven T cell death. II. Quantitative differences alone distinguish stimuli triggering nontransformed T cell proliferation or death
27. The class II MHC I-Ag7 molecules from non-obese diabetic mice are poor peptide binders
28. Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice
29. Functional defects in peripheral blood T cells of multiple sclerosis patients. Diminished in vitro responsiveness in accessory cell dependent activation systems
30. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents
31. Biological activity of gamma interferon
32. Role of interferons and other cytokines in the regulation of the immune response
33. Induction of Ly-6A/E expression by murine lymphocytes after in vivo immunization is strictly dependent upon the action of IFN-alpha/beta and/or IFN-gamma
34. Sequences and factors: A guide to MHC class-II transcription
35. Markers of mouse macrophage development detected by monoclonal antibodies
36. CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model
37. Critical influences of the cytokine orchestration on the outcome of myelin antigen-specific T-cell autoimmunity in experimental autoimmune encephalomyelitis and multiple sclerosis
38. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases
39. Helper T cell differentiation is controlled by the cell cycle
40. Functional analysis of cloned macrophage hybridomas. VII. Modulation of suppressor T cell-inducing activity
41. Effect of adjuvant therapy on development of diabetes in mouse and man
42. Suppression of development of diabetes in NOD mice by lactate dehydrogenase virus infection
43. Prevention of type I diabetes in NOD mice by adjuvant immunotherapy
44. Immunomodulation of experimental autoimmune encephalomyelitis by staphylococcal enterotoxin D
45. Infection of mice with lactic dehydrogenase virus prevents development of experimental allergic encephalomyelitis
46. Interferon-gamma confers resistance to experimental allergic encephalomyelitis
47. Suppression of experimental allergic encephalomyelitis by intraventricular administration of interferon-gamma in Lewis rats
48. Enhancement of experimental allergic encephalomyelitis in mice by antibodies against IFN-gamma